In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Cow cells to couture: Qorium raises $25M for cultivated leather
In the Netherlands, lab-grown leather startup Qorium has raised $25 million to increase its production capabilities and continue to establish commercial partnerships in high-end...
Acclaimed restaurant Noma partners with Novonesis to “take deliciousness to the next level”
In Denmark, Michelin star-mainstay Noma has partnered with biosolutions leader Novonesis to determine the potential of new biobased food ingredients within the Noma Projects...
KAIST team demonstrates use of bacteria to produce and dye cellulose
In South Korea, researchers have coaxed living bacteria to grow, weave, and dye fabrics without the use of oil, plastic or artificial dyes.
The...